Previous 10 | Next 10 |
-- Strong Second Quarter Fiscal 2020 Revenues of $19.3M; Increase of 42% over Second Quarter Fiscal 2019 -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported f...
– Functional Antibodies Identified to S1 Spike Protein and ACE2 Cellular Receptor – Twist Bioscience Corporation (Nasdaq: TWST) today reported it has identified competitive antibodies to SARS-CoV-2, the virus that causes COVID-19, which could potentially be used for di...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2020 second quarter ended March 31, 2020, following the c...
Twist Bioscience Corporation (Nasdaq: TWST) today announced the enhanced Twist Clonal Genes product line with the expansion of preparation quantities, delivery formats, buffer options, and tube and plate options. Customers can now access larger amounts of DNA in the format suitable for their ...
The coronavirus pandemic has disrupted everyday life, altered the trajectory of the global economy, and reminded all of us not to be tricked by the thin veneer of civilization. For all of humanity's advanced technology, our best weapon against a fast-moving virus is to simply stay indoors and ke...
Twist Bioscience (NASDAQ: TWST ) will collaborate with Vanderbilt University Medical Center to supply gene and antibodies for the development of COVID-19 treatments. Also, unit Twist Biopharma will provide custom antibody drug discovery libraries and screen the libraries for potential anti...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the...
CHF Solutions (NASDAQ: CHFS ) announced the use of its Aquadex ultrafiltration therapy to treat volume overload in COVID-19 patients. Shares up 35% premarket. More news on: CHF Solutions, Inc., Endonovo Therapeutics, Inc., Twist Bioscience Corporation, Healthcare stocks ...
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its synthetic SARS-CoV-2 RNA Controls to provide quality control for the development, verification, and ongo...
Twist Bioscience Corporation (Nasdaq: TWST) today announced the availability of Research-Use Only (RUO) target enrichment next-generation sequencing (NGS) panels for viral detection and characterization of samples from patients testing positive for SARS-CoV-2, the virus which causes COVID-19....
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...